First-Line FOLFIRINOX vs Gemcitabine ± Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma: Real-World Treatment Response and Clinicopathologic Predictors from a 2022 Tertiary-Center Cohort
Middle Eastern Cancer and Oncology Journal · 19.04.2026 · 2 (2) · 11-17
DOI: 10.61706/mecoj160191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Middle Eastern Cancer and Oncology Journal, online erschienen am 19.04.2026. Verfasst von Farah Nabil und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The majority of cases of pancreatic ductal adenocarcinoma (PDAC) manifest at a metastatic stage, and the optimal first-line regimen in real-world practice remains the subject of debate. The objective of this study is to compare radiologic response and progression risk across first-line regimens and to evaluate clinicopathologic predictors of outcome in metastatic PDAC. A retrospective cohort study was conducted at the Oncology Teaching Hospital in Baghdad in 2022. The patients were administered FOLFIRINOX, gemcitabine (Gem), or gemcitabine in combination with nab-paclitaxel (GnP). The assessment of outcomes was conducted following the completion of four cycles utilizing the RECIST criteria. Serum CA19‑9 levels were measured prior to and following treatment. Group comparisons employed the appropriate parametric or non-parametric tests, while univariate logistic regression was utilized to estimate odds of progression. The findings indicated that 60 patients were included in the study (mean age 57.9 ± 9.8; 75% male). The median value of CA19‑9 decreased from 213.5 to 83.5 U/mL (P
Zitieren
APA
Nabil, F., & Saleem, M. (2026). First-Line FOLFIRINOX vs Gemcitabine ± Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma: Real-World Treatment Response and Clinicopathologic Predictors from a 2022 Tertiary-Center Cohort. Middle Eastern Cancer and Oncology Journal, 2(2), 11-17. https://doi.org/10.61706/mecoj160191
Vancouver
Nabil F, Saleem M. First-Line FOLFIRINOX vs Gemcitabine ± Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma: Real-World Treatment Response and Clinicopathologic Predictors from a 2022 Tertiary-Center Cohort. Middle Eastern Cancer and Oncology Journal. 2026;2(2):11-17. doi:10.61706/mecoj160191
BibTeX
@article{Nabil2026,
author = {Nabil, Farah and Saleem, Mohammed},
title = {First-Line FOLFIRINOX vs Gemcitabine ± Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma: Real-World Treatment Response and Clinicopathologic Predictors from a 2022 Tertiary-Center Cohort},
journal = {Middle Eastern Cancer and Oncology Journal},
year = {2026},
volume = {2},
number = {2},
pages = {11--17},
doi = {10.61706/mecoj160191}
}
EUVIMED